4A1.F CERENO SCIENTIFIC AB B
- Market cap
- EUR 53.4M
- P/E
- -
- P/B
- 2.56x
- ROE
- -50.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4A1.F undervalued?
Graham numberThe Graham number of CERENO SCIENTIFIC AB B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CERENO SCIENTIFIC AB B fundamental analysis
No fundamental analysis for CERENO SCIENTIFIC AB B yet.
CERENO SCIENTIFIC AB B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue rem…
Full company profileCERENO SCIENTIFIC AB B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CERENO SCIENTIFIC AB B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 44.8M | 57.5M | 49.3M | 80.9M | 44.3M | 154M |
| Operating Income | -14.8M | -26.6M | -44.2M | -73.9M | -74.3M | -78.3M |
| EBITDA | - | -27.2M | -42.8M | -73.2M | -72.4M | -77.6M |
| Net Income | -16.3M | -27.7M | -48.1M | -99.5M | -118M | -115M |
| EPS | -0.15 | -0.20 | -0.21 | -0.35 | -0.38 | -0.36 |
| Balance Sheet | ||||||
| Total Assets | 181M | 216M | 285M | 414M | 403M | 484M |
| Total Liabilities | 10.7M | 14.1M | 68.6M | 222M | 150M | 254M |
| Shareholders' Equity | 170M | 202M | 216M | 192M | 253M | 230M |
| Cash & Short-term Investments | 89.6M | 67.0M | 87.2M | 128M | 74.6M | 40.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -13.1M | -18.6M | -36.9M | -103M | -112M | -43.5M |
| Capital Expenditure | 44.8M | 57.5M | 49.3M | 84.8M | 44.3M | 154M |
| Free Cash Flow | -57.9M | -76.2M | -86.2M | -188M | -156M | -197M |
| Ratios | ||||||
| ROE | -9.6% | -13.7% | -22.2% | -51.9% | -46.6% | -50.1% |
| ROA | -9.0% | -12.8% | -16.9% | -24.1% | -29.2% | -23.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
CERENO SCIENTIFIC AB B dividends
CERENO SCIENTIFIC AB B has not paid dividends in the last 5 fiscal years.
Who owns CERENO SCIENTIFIC AB B
- Insiders 12.21%
- Institutions 20.63%
- Public & others 67.16%
- Shares outstanding 323M
- Free float 260M
CERENO SCIENTIFIC AB B company profile
- Company name
- CERENO SCIENTIFIC AB B
- Ticker
- 4A1.F
- ISIN
- SE0008241558
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10
- Fiscal year end
- December
- Address
- Förändringens gata 10, Gothenburg, Sweden, 431 53
- Phone
- 46 768 66 77 87
- Website
- cerenoscientific.com
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.
CERENO SCIENTIFIC AB B management
6- Mr. Sten R. SorensenCEO & Director · born 1959
- Ms. Eva JagenheimChief Financial Officer · born 1966
- Dr. Bjorn Dahlof FACC, FESC, M.D., Ph.D.Chief Scientific Officer · born 1953
- Mr. Fredrik FrickHead of Clinical Operations · born 1973
- Mr. Nicholas OakesHead of Preclinical Development · born 1961
- Dr. Rahul Agrawal M.D.Chief Medical Officer & Head of R&D · born 1965